'What Is Microbiologic Success?': Rare Lung Infection Is Microcosm Of Antibiotic Development Challenges
This article was originally published in The Pink Sheet Daily
FDA is working hard on expanded access program for patients with non-tuberculous mycobacterial (NTM) lung infections; there is no approved drug for the condition in part because of the difficulty in defining trial endpoints.
Register for our free email digests: